Kymathera raises $80 million Series B financing
Kymathera announced an $80 million Series B financing led by Alta Partners to advance K-1728, a next-generation selective Pi3kα inhibitor for cancer and vascular malformations.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Kymathera Raises $80 Million Series B To Advance Cancer Drug K-1728
Kymathera has announced an $80 million Series B financing round to advance its next-generation pan-mutant selective Pi3kα inhibitor, K-1728, for the treatment of cancer and vascular malformations.